Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 19, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not report company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions executed on the New York Stock Exchange (XNYS) on July 17, 2018.
| Executive | Position | Transaction Type | Price per ADS | Volume (ADSs) |
|---|---|---|---|---|
| Mr. N. Hirons | SVP, Global Ethics & Compliance | Acquisition (Dividend Re-investment) | $41.1815 | 18.276 |
| Mr. B. McNamara | CEO, GSK Consumer Healthcare | Acquisition (Dividend Re-investment) | $41.1815 | 412.270 |
| Mr. D. E. Troy | SVP & General Counsel | Acquisition (Dividend Re-investment) | $41.1815 | 2,206.084 |
Material Changes
The filing does not provide comparative financial data or material changes in the company's operational performance versus prior periods. The only reported activity is the acquisition of American Depositary Shares (ADSs) by the named executives following the re-investment of dividends paid to shareholders on July 12, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific share transactions.
Investor Verification Checklist
- Verify that the share acquisitions were executed strictly as part of a dividend re-investment plan.
- Confirm the transaction date of July 17, 2018, aligns with the dividend payment date of July 12, 2018.
- Check the New York Stock Exchange (XNYS) records for the execution price of $41.1815 per ADS.
- Ensure the total volume of shares acquired by each executive matches the disclosed figures.